| INTRODUCTION
D-2-hydroxyglutaric aciduria (D-2-HGA) is a rare neurometabolic disorder with broad phenotypic heterogeneity (Kranendijk, Struys, Salomons, Van der Knaap, & Jakobs, 2012; van der Knaap, Jakobs, Hoffmann, Duran et al., 1999; van der Knaap, Jakobs, Hoffmann, Nyhan et al., 1999) . Developmental delay, hypotonia, and seizures are the most frequently observed clinical signs. D-2-HGA Type I (MIM# 600721) is caused by recessive variants in D2HGDH, the gene encoding D-2-hydroxyglutarate dehydrogenase (D-2-HGDH, MIM# 609186; . D-2-HGDH is a mitochondrial, FAD-binding enzyme (Achouri et al., 2004) , belonging to the α-hydroxy acid dehydrogenases subgroup of the para-cresol methylhydroxylase flavoprotein family (Fraaije, Van Berkel, Benen, Visser, & Mattevi, 1998) . D-2-HGA Type II (MIM# 613657) is caused by specific heterozygous gain of function variants in IDH2, the gene encoding isocitrate dehydrogenase 2 (MIM# 147650; Kranendijk, Struys, van Schaftingen et al., 2010) . In both types, the biochemical hallmarks are increased levels of D-2-hydroxyglutarate (D-2-HG) in body fluids due to either an impaired D-2-HGDH enzyme activity (Type I) or overproduction of D-2-HG (Type II). The accumulation of 2-hydroxyglutarate (2-HG) is usually detected by routine urinary organic acid screening. Since these methods are incapable of separating D-and L-2-HG, a dedicated chiral-based assay is required to establish the biochemical diagnosis of D-2-HGA (Struys, Jansen, Verhoeven, & Jakobs, 2004) . In the past, enzyme activity tests in fibroblasts or lymphoblasts derived from patients (Kranendijk et al., 2011; Wickenhagen, Salomons, Gibson, Jakobs, & Struys, 2009 ) and genetic studies were used for confirmation of the diagnosis. Implementation of next generation sequencing methodologies has resulted in molecular analysis supplanting enzymology as the first-tier testing approach.
Thus far, 32 variants in the D2HGDH gene have been described in patients with D-2-HGA (The Human Gene Mutation Database), of which 21 are missense variants (Ali Pervaiz et al., 2011; Haliloglu et al., 2009; Misra et al., 2005; Struys, Korman et al., 2005; Struys et al., 2006) . To date, only three of these variants have been characterized via overexpression studies (Struys, Korman et al., 2005 . Truncating variants are usually classified as pathogenic, whereas inferring the pathogenicity of missense variants is more challenging. Bioinformatic prediction tools are important for estimating the potential of missense variants to disturb protein function but do not confirm the pathogenicity, and sometimes may fail to give correct predictions (Frigeni et al., 2017) .
Therefore, functional studies via site-directed mutagenesis and enzyme assay remain pivotal in the characterization of variants of unknown significance.
Here, we describe a functional assay to characterize missense variants in the D2HGDH gene, while simultaneously reporting the functional evaluation of 10 novel missense variants in conjunction with 21 previously reported missense variants.
| MATERIALS AND METHODS

| Variant analysis
The coding region of the D2HGDH gene was analyzed as described . All 10 exons and the adjacent splice sites were amplified and sequenced using an ABI PRISM 3130xl Genetic Analyser (Applied Biosystems, Foster City, CA) with interpretation using Mutation Surveyor (Softgenetics, State College, PA). Nucleotide numbering of the variants reflects cDNA numbering in which +1 corresponds to the A of the ATG translation initiation codon in the reference sequence (NM_152783.3).
| Bioinformatic prediction of pathogenicity of missense variants
Pathogenicity potential of the studied variants was estimated using three prediction software tools: PolyPhen-2 (Adzhubei et al., 2010) , SIFT (Ng & Henikoff, 2003) , and MutationTaster (Schwarz, Cooper, Schuelke, & Seelow, 2014) integrated in the Alamut Visual software package, version 2.9 (Interactive Biosoftware, Rouen, France). The potential effect of the variants on messenger RNA (mRNA) splicing was also evaluated using in silico splice tools: MaxEntScan, NNsplice, and Human Splicing Finder (Alamut Visual software, version 2.9). To study sequence conservation, human and 10 homologous D-2-HGDH protein sequences were retrieved from the Universal Protein Knowledgebase (UniProt) and aligned using the Clustal Omega program (Sievers et al., 2011) . Identical and/or similar amino acids were highlighted using BOXSHADE (https://embnet.vital-it.ch/ software/BOX_form.html).
| Site-directed mutagenesis
The pCMV5-D2HGDH wild type construct was used for site-directed mutagenesis and overexpression (Achouri et al., 2004) . Variants were introduced in the D2HGDH open reading frame using specific primers (Table S1 ; Betsalel et al., 2012) . Successful mutagenesis (as well as the absence of PCR artifacts) was confirmed by full-length sequencing of D2HGDH. 
| Overexpression of missense variants in HEK293 cells
| Detection of overexpressed D-2-HGDH proteins
To verify successful transfection, SDS PAGE/Western blot analysis was performed as described (Pop et al., 2018) 
| D-2-HGDH enzyme activity of transfectants
D-2-HGDH enzyme activity was assessed as described (Wickenhagen et al., 2009) , and was optimized with respect to protein concentration, reaction time, and substrate concentration. Cell pellets were resuspended in assay buffer, disrupted by sonication, and homogenates were clarified by centrifugation. The protein content of lysates was determined by Bicinchoninic acid assay (Sigma-Aldrich), and samples were adjusted to 0.14 mg/ml protein. 
| Functional analysis of D2HGDH missense variants
The effect of the missense variants on the function of D-2-HGDH enzyme was studied by overexpression in HEK293 cells. In total, 31 missense variants were analyzed, including 10 novel variants.
All variants were independently introduced in the coding region of the D2HGDH gene and the resulting recombinant constructs as well as the appropriate controls, were overexpressed in HEK293 D-2-HG excretion and diagnosed with other metabolic diseases. The p.Gly436Val variant (87% residual activity) was detected in a patient with succinic semialdehyde dehydrogenase (SSADH) deficiency (Struys et al., 2006) , and the novel variant, p.Leu453Phe (68% residual activity), was found in a patient diagnosed with D-2-HGA Type II. The mild effect of these variants on D-2-HGDH activity and the fact that they are found in heterozygous state in patients diagnosed with other metabolic deficiencies suggests they are likely rare nonpathogenic variants (Table 1) . However, we cannot exclude that the mild decrease in D-2-HGDH activity could also contribute to the phenotype of these SSADH or D-2-HGA Type II patients.
p.Ala392Gly (59% residual activity) was detected in the heterozygous state as the sole potentially pathogenic allele in one patient.
Patient-derived fibroblast analyses revealed a complete impairment of D-2-HGDH activity. Yet, the clinical significance of the p.Ala392Gly variant is not fully elucidated, and therefore we cannot exclude that other unidentified variants may exist.
p.Ala446Val displays 67% residual activity. Conservation of Ala446 is poor across D-2-HGDH orthologs ( Figure S2 ) and the software prediction tools predict the p.Ala446Val variant as benign (Table S2) . Taken together, these data suggest that p.Ala446Val is (Table S2) did not alter protein homodimerization or intracellular localization (Lin et al., 2015) . Eventual crystallization and x-ray diffraction analyses of D-2-HGDH will be illuminating in placing the variants we have identified within a 3-dimensional context.
D2HGDH transcriptional regulation studies in colorectal cancer
have recently been reported (Han et al., 2018) . These investigators identified a putative Hif-1α transcription factor binding site in the D2HGDH promoter, suggesting that Hif-1α controls both the expression of D-2-HGDH as well as D-2-HG levels. Comparable promoter studies are needed in our patients for whom variants with high residual activities and/or a single potentially pathogenic allele, were identified.
The pathogenicity potential of the studied variants was also estimated using PolyPhen-2, SIFT and MutationTaster prediction software tools (Alamut Visual software package, version 2.9; Table   S2a 
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